在日本患有心血管疾病的患者中的脂蛋白:系统性审查

相关实验视频

Updated: Jan 15, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Hiroshi Yoshida¹, Michel Kroes², Yoko Sakai³

¹Jikei University Kashiwa Hospital, Chiba, Japan.

|October 7, 2025

概括

升高的脂蛋白[Lp[a]与日本人的心血管疾病 (CVD) 风险增加有关. 这一综述强调了一致的关联,尽管对高Lp (a) 水平的定义有所不同.

科学领域:

心脏病学心脏病学
生物化学生物化学
流行病学流行病学

背景情况:

脂蛋白 (Lp) 是已确定的心血管疾病 (CVD) 的独立风险因素.
有限的数据存在于Lp(a) 水平及其与CVD的关联,特别是在日本人口中.
对于全球心血管健康策略来说,了解不同族群中的Lp (a) 是至关重要的.

研究的目的:

系统地审查和综合现有证据,关于日本患者的Lp(a) 水平和心血管疾病之间的关联.
评估升高的Lp (a) 对心血管风险在这个特定的人群中的影响.
用标准化免疫检测方法整合发现,以实现可比性.

主要方法:

对调查日本患者的Lp(a) 和心血管疾病的研究进行系统文献综述.
专注于使用基于LATEX的免疫测试方法进行一致的Lp (a) 测量的研究.
集中分析了从"高"Lp(a) 水平分类的患者组的发现.

主要成果:

在日本人群中观察到升高的Lp(a) 与心血管风险增加之间存在一致的关联.
这些发现与国际数据一致,证实了Lp (a) 在不同人群中对心血管疾病的作用.
结果的变化被注意到,归因于研究设计,终点和随访持续时间的差异.

结论:

升高的Lp (a) 是日本人口中显著的心血管风险因素,与全球观察一致.
需要进一步的研究,以充分阐明高Lp的临床影响 (a) 在日本人.
虽然没有针对Lp(a) 的特定疗法得到批准,但正在进行的临床试验可能会为未来的治疗选择提供选择.

关键词:

心血管疾病心血管疾病脂蛋白 (a) 是一种蛋白质二次预防二次预防.

更多相关视频

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

相关概念视频

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Rheumatic Heart Disease III: Medical Management

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...